company background image
42C logo

iX Biopharma Catalist:42C Stock Report

Last Price

S$0.022

Market Cap

S$19.4m

7D

-4.3%

1Y

-51.1%

Updated

30 Dec, 2024

Data

Company Financials

iX Biopharma Ltd.

Catalist:42C Stock Report

Market Cap: S$19.4m

42C Stock Overview

A specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. More details

42C fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Does not have meaningful revenue (SGD6M)

Shareholders have been diluted in the past year

Does not have a meaningful market cap (SGD19M)


My Notes

Capture your thoughts, links and company narrative

iX Biopharma Ltd. Competitors

Pharmesis International

SGX:BFK

S$18.2m

Hyphens Pharma International

Catalist:1J5

S$88.0m

Haw Par

SGX:H02

S$2.5b

Charlotte's Web Holdings

TSX:CWEB

CA$18.9m

Price History & Performance

Summary of share price highs, lows and changes for iX Biopharma
Historical stock prices
Current Share PriceS$0.022
52 Week HighS$0.057
52 Week LowS$0.022
Beta0.82
1 Month Change-8.33%
3 Month Change-15.38%
1 Year Change-51.11%
3 Year Change-89.27%
5 Year Change-90.22%
Change since IPO-96.07%

Recent News & Updates

Recent updates

Shareholder Returns

42CSG PharmaceuticalsSG Market
7D-4.3%0.8%1.1%
1Y-51.1%7.4%11.2%

Return vs Industry: 42C underperformed the SG Pharmaceuticals industry which returned 7.6% over the past year.

Return vs Market: 42C underperformed the SG Market which returned 10.6% over the past year.

Price Volatility

Is 42C's price volatile compared to industry and market?
42C volatility
42C Average Weekly Movement7.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement4.4%
10% most volatile stocks in SG Market13.0%
10% least volatile stocks in SG Market1.9%

Stable Share Price: 42C has not had significant price volatility in the past 3 months compared to the SG market.

Volatility Over Time: 42C's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200442Eddy Leewww.ixbiopharma.com

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia.

iX Biopharma Ltd. Fundamentals Summary

How do iX Biopharma's earnings and revenue compare to its market cap?
42C fundamental statistics
Market capS$19.43m
Earnings (TTM)-S$10.79m
Revenue (TTM)S$5.96m

3.3x

P/S Ratio

-1.8x

P/E Ratio

Is 42C overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
42C income statement (TTM)
RevenueS$5.96m
Cost of RevenueS$4.91m
Gross ProfitS$1.05m
Other ExpensesS$11.84m
Earnings-S$10.79m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin17.59%
Net Profit Margin-181.14%
Debt/Equity Ratio107.6%

How did 42C perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 04:36
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iX Biopharma Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lee Keng LingDBS Bank Ltd
Paul ChewPhillip Securities Pte Ltd
Wee Kuang TayPhillip Securities Pte Ltd